Erratum: Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase i trials (Invest New Drugs DOI: 10.1007/s10637-011-9671-z);Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase i trials

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 1116-1120

  Levy, Antonin ^a,b   Albiges Sauvin, Laurence ^a   Massard, Christophe ^a   Izzedine, Hassan ^c   Edhery, Stéphane ^a   Bahleda, Ratio ^a   Gomez Roca, Carlos ^a   Chargari, Cyrus ^b   Brocheriou Spelle, Isabelle ^c   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antiangiogenics; Cancer; Phase I; Renal toxicity

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IRINOTECAN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOPROTEIN RECEPTOR INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MESOTHELIOMA; OUTCOME ASSESSMENT; PAROTID GLAND CANCER; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SARCOMA; SOLID TUMOR; TREATMENT DURATION; UTERINE CERVIX CANCER;

EID: 84864368280     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9783-5     Document Type: Erratum

References (25)

1. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187 (Pubitemid 41058349)
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 (Pubitemid 32222155)
3. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecita-bine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743 (Pubitemid 46021510)
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345 (Pubitemid 38944402)
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
6. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578 (Pubitemid 43209104)
7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
9. Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601-5608 (Pubitemid 46631341)
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134 (Pubitemid 46089673)
11. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
12. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, AVOREN Trial investigators (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103-2111 (Pubitemid 350296300)
13. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon Alfa compared with interferon Alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428
14. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms ofanti-tumour activity. Nat Rev Cancer 8:579-591
15. Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475-485 (Pubitemid 46809172)
16. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332-344 (Pubitemid 46652481)
17. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50:203-218 (Pubitemid 47095077)
18. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67:2089-2100 (Pubitemid 41623371)
19. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
20. Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354:2473-2483 (Pubitemid 43855050)
21. Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48:9-17
22. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE (2008) VEGF inhibition and renal thrombotic microangiopathy N Engl J Med 358:1129-1136 (Pubitemid 351398487)
23. Izzedine H, Sène D, Hadoux J, Gharbi C, Bourry E, Massard C, Soria JC (2011) Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment? Ann Oncol 22:487-490
24. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G, Renal Insufficiency and Cancer Medications (IRMA) Study Group (2007) Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insuf-ficiency and anticancer medications (IRMA) study. Cancer 110:1376-1384 (Pubitemid 47435612)
25. Launay-Vacher V, Ayllon J, Janus N, Medioni J, Deray G, Isnard-Bagnis C, Oudard S (2009) Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. Urol Oncol